These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

915 related items for PubMed ID: 24355040

  • 1. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, Saghir A, Blast Study Group.
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [Abstract] [Full Text] [Related]

  • 2. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
    Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S.
    BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
    [Abstract] [Full Text] [Related]

  • 3. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
    Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P.
    J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
    [Abstract] [Full Text] [Related]

  • 4. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study.
    Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, BLAST Study Group.
    J Sex Med; 2014 Mar; 11(3):840-56. PubMed ID: 24308723
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale.
    Ho CC, Tong SF, Low WY, Ng CJ, Khoo EM, Lee VK, Zainuddin ZM, Tan HM.
    BJU Int; 2012 Jul; 110(2):260-5. PubMed ID: 22093057
    [Abstract] [Full Text] [Related]

  • 6. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study.
    Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S.
    Andrology; 2017 Sep; 5(5):905-913. PubMed ID: 28771964
    [Abstract] [Full Text] [Related]

  • 7. Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial.
    Gianatti EJ, Dupuis P, Hoermann R, Zajac JD, Grossmann M.
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3821-8. PubMed ID: 24978674
    [Abstract] [Full Text] [Related]

  • 8. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M.
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [Abstract] [Full Text] [Related]

  • 9. 12-month observation of testosterone replacement effectiveness in a general population of men.
    Miner MM, Bhattacharya RK, Blick G, Kushner H, Khera M.
    Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
    [Abstract] [Full Text] [Related]

  • 10. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
    Permpongkosol S, Tantirangsee N, Ratana-olarn K.
    J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
    [Abstract] [Full Text] [Related]

  • 11. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG, Park MG, Lee SW, Park K, Park JK, Kim SW, Park NC, Ahn TY, Paick JS, Seo JT, Yang DY, Lee JY, Kim JJ.
    J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
    [Abstract] [Full Text] [Related]

  • 12. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G.
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [Abstract] [Full Text] [Related]

  • 13. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF, Reid M, Madden W, Burnett AL.
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [Abstract] [Full Text] [Related]

  • 14. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome.
    Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY.
    J Sex Med; 2010 Jul; 7(7):2572-82. PubMed ID: 20524974
    [Abstract] [Full Text] [Related]

  • 15. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only.
    Yassin AA, Saad F.
    J Sex Med; 2007 Mar; 4(2):497-501. PubMed ID: 17367445
    [Abstract] [Full Text] [Related]

  • 16. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S, Khupulsup K, Leelaphiwat S, Pavavattananusorn S, Thongpradit S, Petchthong T.
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [Abstract] [Full Text] [Related]

  • 17. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
    Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, Eastell R, Wu F, Ross RJ.
    Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
    [Abstract] [Full Text] [Related]

  • 18. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R, Swinburne J, Orme S.
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [Abstract] [Full Text] [Related]

  • 19. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
    Reyes-Vallejo L, Lazarou S, Morgentaler A.
    J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
    [Abstract] [Full Text] [Related]

  • 20. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, Louis ED, Mulligan T, Foster PS, Shenal BV, Armaghani SJ, Jacobson C, Wu S, Crucian G.
    Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.